Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients

  • September 11, 2026

  • 2 min

Share

Clinical Scorecard: Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

At a Glance

CategoryDetail
ConditionCell and Gene Therapy
Key MechanismsTransformative potential for serious diseases, high manufacturing costs, complex delivery pathways.
Target PopulationPatients requiring advanced therapies for serious diseases.
Care SettingRoutine care transitioning from clinical trials.

Key Highlights

  • High manufacturing costs restrict patient access to therapies.
  • Need for assessing long-term value rather than just upfront costs.
  • Importance of treating patients earlier in the disease process.
  • Expansion of delivery methods beyond specialist centers.
  • Collaboration among manufacturers, regulators, and healthcare systems is essential.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with serious diseases requiring cell and gene therapies.

          Access to therapies is limited by costs and delivery complexities.

          Clinical Best Practices

          • Reduce production costs for therapies.
          • Focus on long-term value assessment.
          • Collaborate across sectors to improve access.

          Related Resources & Content

            Original Source(s)

            Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

            • September 11, 2026

            Related Content

            Correction: Qingzhu granule mitigates acute gouty arthritis through HIF-1a-dependent glycolytic metabolic reprogramming of M1 macrophages

            Adenotonsillectomy linked to more RTI visits

            The findings suggest adenotonsillectomy should not be performed solely to prevent respiratory tract infections in pediatric patients.

            Pima Medical Institute Launches Dental Hygiene Program in Phoenix

            New 18-month curriculum includes classroom, laboratory and clinical education for students pursuing associate degrees.

            • September 11, 2026

            • 3 min